Cargando…
Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
This study aimed to analyze the association between driver mutations and predictive markers for some anti–tumor agents in non–small cell lung cancer (NSCLC). A cohort of 785 Chinese patients with NSCLC who underwent resection from March 2016 to November 2017 in the First Affiliated Hospital of Guang...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549909/ https://www.ncbi.nlm.nih.gov/pubmed/31033100 http://dx.doi.org/10.1111/cas.14032 |
_version_ | 1783424089348636672 |
---|---|
author | Liang, Wenhua Guo, Minzhang Pan, Zhenkui Cai, Xiuyu Li, Caichen Zhao, Yi Liang, Hengrui Yang, Haiying Wang, Zhen Chen, Wenting Xu, Chuhong Yang, Xinyun Sun, Jianyu He, Ping Gu, Xia Yin, Weiqiang He, Jianxing |
author_facet | Liang, Wenhua Guo, Minzhang Pan, Zhenkui Cai, Xiuyu Li, Caichen Zhao, Yi Liang, Hengrui Yang, Haiying Wang, Zhen Chen, Wenting Xu, Chuhong Yang, Xinyun Sun, Jianyu He, Ping Gu, Xia Yin, Weiqiang He, Jianxing |
author_sort | Liang, Wenhua |
collection | PubMed |
description | This study aimed to analyze the association between driver mutations and predictive markers for some anti–tumor agents in non–small cell lung cancer (NSCLC). A cohort of 785 Chinese patients with NSCLC who underwent resection from March 2016 to November 2017 in the First Affiliated Hospital of Guangzhou Medical University was investigated. The specimens were subjected to hybridization capture and sequence of 8 important NSCLC‐related driver genes. In addition, the slides were tested for PD‐L1, excision repair cross‐complementation group 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthase (TS) and β‐tubulin III by immunohistochemical staining. A total of 498 (63.4%) patients had at least 1 driver gene alteration. Wild‐type, EGFR rare mutation (mut), ALK fusion (fus), RAS mut, RET fus and MET mut had relatively higher proportions of lower ERCC1 expression. EGFR 19del, EGFR L858R, EGFR rare mut, ALK fus, HER2 mut, ROS1 fus and MET mut were more likely to have TS low expression. Wild‐type, EGFR L858R, EGFR rare mut and BRAF mut were associated with lower β‐tubulin III expression. In addition, wild‐type, RAS mut, ROS1 fus, BRAF and MET mut had higher proportion of PD‐L1 high expression. As a pilot validation, 21 wild‐type patients with advanced NSCLC showed better depth of response and response rate to taxanes compared with pemetrexed/gemcitabine (31.2%/60.0% vs 26.6%/45.5%). Our study may aid in selecting the optimal salvage regimen after targeted therapy failure, or the chemo‐regimen where targeted therapy has not been a routine option. Further validation is warranted. |
format | Online Article Text |
id | pubmed-6549909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65499092019-06-07 Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition Liang, Wenhua Guo, Minzhang Pan, Zhenkui Cai, Xiuyu Li, Caichen Zhao, Yi Liang, Hengrui Yang, Haiying Wang, Zhen Chen, Wenting Xu, Chuhong Yang, Xinyun Sun, Jianyu He, Ping Gu, Xia Yin, Weiqiang He, Jianxing Cancer Sci Original Articles This study aimed to analyze the association between driver mutations and predictive markers for some anti–tumor agents in non–small cell lung cancer (NSCLC). A cohort of 785 Chinese patients with NSCLC who underwent resection from March 2016 to November 2017 in the First Affiliated Hospital of Guangzhou Medical University was investigated. The specimens were subjected to hybridization capture and sequence of 8 important NSCLC‐related driver genes. In addition, the slides were tested for PD‐L1, excision repair cross‐complementation group 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthase (TS) and β‐tubulin III by immunohistochemical staining. A total of 498 (63.4%) patients had at least 1 driver gene alteration. Wild‐type, EGFR rare mutation (mut), ALK fusion (fus), RAS mut, RET fus and MET mut had relatively higher proportions of lower ERCC1 expression. EGFR 19del, EGFR L858R, EGFR rare mut, ALK fus, HER2 mut, ROS1 fus and MET mut were more likely to have TS low expression. Wild‐type, EGFR L858R, EGFR rare mut and BRAF mut were associated with lower β‐tubulin III expression. In addition, wild‐type, RAS mut, ROS1 fus, BRAF and MET mut had higher proportion of PD‐L1 high expression. As a pilot validation, 21 wild‐type patients with advanced NSCLC showed better depth of response and response rate to taxanes compared with pemetrexed/gemcitabine (31.2%/60.0% vs 26.6%/45.5%). Our study may aid in selecting the optimal salvage regimen after targeted therapy failure, or the chemo‐regimen where targeted therapy has not been a routine option. Further validation is warranted. John Wiley and Sons Inc. 2019-05-22 2019-06 /pmc/articles/PMC6549909/ /pubmed/31033100 http://dx.doi.org/10.1111/cas.14032 Text en © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Liang, Wenhua Guo, Minzhang Pan, Zhenkui Cai, Xiuyu Li, Caichen Zhao, Yi Liang, Hengrui Yang, Haiying Wang, Zhen Chen, Wenting Xu, Chuhong Yang, Xinyun Sun, Jianyu He, Ping Gu, Xia Yin, Weiqiang He, Jianxing Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
title | Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
title_full | Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
title_fullStr | Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
title_full_unstemmed | Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
title_short | Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
title_sort | association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549909/ https://www.ncbi.nlm.nih.gov/pubmed/31033100 http://dx.doi.org/10.1111/cas.14032 |
work_keys_str_mv | AT liangwenhua associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT guominzhang associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT panzhenkui associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT caixiuyu associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT licaichen associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT zhaoyi associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT lianghengrui associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT yanghaiying associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT wangzhen associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT chenwenting associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT xuchuhong associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT yangxinyun associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT sunjianyu associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT heping associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT guxia associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT yinweiqiang associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition AT hejianxing associationbetweencertainnonsmallcelllungcancerdrivermutationsandpredictivemarkersforchemotherapyorprogrammeddeathligand1inhibition |